Released on = February 8, 2006, 5:52 am

Press Release Author = Anna Oderda

Industry = Biotech

Press Release Summary = A new biotech start-up in Italy - Professor Marco Bianchi
and Creabilis Therapeutics announce the creation of HMGBiotech Srl.


Press Release Body = Milan, Italy and Colleretto Giacosa (Turin), Italy, 6 February
2006 - Marco Bianchi, Professor of Molecular Biology, and Creabilis Therapeutics
S.p.A., are very pleased to announce the creation of a new company named HMGBiotech.

The company is based in Milan, with one laboratory at the Centro Cardiologico
Fondazione Monzino, via Parea 4, Milano, and a second one in Colleretto Giacosa, at
the Bioindustry Park of Canavese.
The mission of the company is to exploit the opportunities offered by the HMGB
proteins as therapeutic target. In particular, the initial activity of the company
is focused on the preparation of HMGB proteins and their fragments, including Box A
and Box B. These materials will be offered to other companies and academic
institutions. In addition to this activity the company is planning to set up a
method for the determination of HMGB1 in biological fluids.
Additional services are represented by the possibility of evaluating the inhibitory
activity of potential HMGB's inhibitors, by means of tests of inhibition of cell
proliferation and migration induced by HMGB proteins.

Creabilis Therapeutics S.p.A. participates to this initiative with 10% of equities.
HMGBiotech will collaborate with both Creabilis Therapeutics and Bio3 Research,
which are already collaborating with Prof. M. Bianchi.

Marco Bianchi, HMGBiotech's CEO, said: "HMGB1 has been identified as an important
effector of inflammation and innate immunity, and is involved in sepsis and other
widespread diseases, such as rheumatoid arthritis and atherosclerosis. I strongly
believe that no clinical research can be meaningful without a solid basic knowledge.
For this reason, HMGBiotech's mission is to provide the reagents, validated
methodologies and tests which will help and support the research in this extremely
interesting field."

Silvano Fumero, Creabilis Therapeutics S.p.A.'s CEO, said "The participation in
HMGBiotech is an important strategic asset for our company, because part of our
project portfolio is based on HMGB1 as therapeutical target. In addition the
location of one of HMGBiotech's laboratories inside the Bioindustry Park will
improve the performance of our already well established collaboration".

Roberto Ricci, Managing Director of the Bioindustry Park of Canavese, said:
"HMGBiotech increases the presence of biotech companies inside the Bioindustry Park,
8 initiatives in total, with more than 30 researchers: the first biotech start-up
cluster in Italy. Professor Marco Bianchi, scientist of international reputation,
increases the presence of academic people in the Park, demonstrating that, with
favourable conditions, public and private research initiatives are able to produce
stimulating opportunities for the entrepreneurial development".



About Creabilis Therapeutics S.p.A.
Creabilis Therapeutics S.p.A. is a privately owned drug-discovery and development
company, founded in 2003 and located in the Bioindustry Park of Canavese, near
Turin. The main research areas are inflammation, autoimmune diseases, psoriasis and
AIDS.
Additional information on Creabilis Therapeutics can be obtained from
www.creabilistherapeutics.com or by e-mail: info@creabilistherapeutics.com




Web Site = http://www.creabilistherapeutics.com

Contact Details = creabilis therapeutics SpA
Via Ribes 5 10010 Colleretto Giacosa (TO) Italy 0039.0125.53543
info@creabilistherapeutics.com